Tackling today’s top challenges of clinical research

Video
Conference|ARVO

Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.

David Hutton, executive editor of Ophthalmology Times®, sits down with Michael Watson, Vice President of OraNet to discuss this year’s most pressing challenges in clinical research: From the overburdening of sites with studies delayed by COVID to difficulties with staff retention and how holistic site support and patient solutions can provide enough to relief to keep projects on time and within budget.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Alexandra Miere, MD, PhD, Associate Professor of Ophthalmology, University Paris Est Créteil, France, speaks at EURETINA
Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.
Related Content
A red DNA strand on a yellow-and-white background. Image credit: ©abhijith3747 – stock.adobe.com

Treatment and technology: The future of retina care

Marta Stevanovic, MD, MSc
October 7th 2024
Article

How robotics and gene therapies are shaping retina research, now and in the days to come

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A road sign with a brain on it in front of a highway. Image credit: ©Prime Lens – stock.adobe.com

Alzheimer disease retinopathy and brain-to-eye β-amyloid transport

Lynda Charters
October 4th 2024
Article

The research findings highlighted a new therapeutic avenue in ocular and neurodegenerative disease

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Image credit: ©Who is Danny – stock.adobe.com

What's missing in patient education?

Albert J. Augustin, MD
October 3rd 2024
Article

A different approach better serves patients with diabetic retinopathy

A phone and computer with the European Medicines Agency website. Image credit: ©Timon – stock.adobe.com

EU CHMP confirms negative opinion on marketing authorisation application of intravitreal pegcetacoplan from Apellis

Martin David Harp
September 25th 2024
Article

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response

© 2024 MJH Life Sciences

All rights reserved.